Search
Alumis Inc
ALMSAdd to Watchlist
28.140USD
+1.000+3.68%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.59BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.68%
5 Days
+14.81%
1 Month
+30.28%
6 Months
+188.32%
Year to Date
+188.32%
1 Year
+838.00%
Key Figures
27.250Open
28.650High
2.34MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.24%Turnover Ratio
27.140Prev. Close
26.800Low
49.18MTurnover
LossP/E Static
9.78P/B
0.00%Div Yield TTM
-50.90%ROA
30.60052wk High
1.05Volume Ratio
-294.23MNet Profit
104.71MShares
-1.7826EPS TTM
--Beta
-86.68%ROE
2.76052wk Low
6.82%Amplitude
100.00%Gross Margin
3.59BMarket Cap
6.89Reward/Risk
4.86%Risk Rate
TradingKey Stock Score of Alumis Inc
Currency: USD Updated: 2026-06-30Key Insights
Alumis Inc's fundamentals are relatively healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 87 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.10.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alumis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Alumis Inc Highlights
StrengthsRisks
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.05M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.05M.
Undervalued
The company’s latest PE is -15.79, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 100.94M shares, increasing 17.49% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 491.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.34.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
40.100
Target Price
+47.75%
Upside Space
Alumis Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alumis Inc Info
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Ticker SymbolALMS
CompanyAlumis Inc
CEOBabler (Martin)
Websitehttps://www.alumis.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of Alumis Inc (ALMS)?
The current price of Alumis Inc (ALMS) is 28.14.
What is the symbol of Alumis Inc?
The ticker symbol of Alumis Inc is ALMS.
What is the 52-week high of Alumis Inc?
The 52-week high of Alumis Inc is 30.60.
What is the 52-week low of Alumis Inc?
The 52-week low of Alumis Inc is 2.76.
What is the market capitalization of Alumis Inc?
The market capitalization of Alumis Inc is 2.95B.
Is Alumis Inc (ALMS) currently rated as Buy, Hold, or Sell?
According to analysts, Alumis Inc (ALMS) has an overall rating of Buy, with a price target of 40.10.
What is the Earnings Per Share (EPS TTM) of Alumis Inc (ALMS)?
The Earnings Per Share (EPS TTM) of Alumis Inc (ALMS) is -2.86.